On the morning of December 16, the Chinese University of Hong Kong, Shenzhen (CUHK-Shenzhen), awarded the First Honorary Fellowship to the following four outstanding individuals in recognition of their remarkable achievements in their respective

In October 2021, Shanghai Securities News' "Innovation China" visited Kexing Biopharm and interviewed Chairman Deng Xueqin. In the interview, Deng Xueqin went into detail explaining the development history of Kexing Biopharm.

The signing & opening ceremony of "Kexing Biopharm - Southeast University Innovation Laboratory for Commercial Production of Extracellular Vesicle-based Drug Delivery Technology" successfully held!

Following the NMPA's approval for the marketing application of infliximab biosimilar (CMAB008) on July 14, Kexing Biopharm quickly started working on an overseas sales plan for the drug.

Following the NMPA's approval for the marketing application of infliximab biosimilar (CMAB008) on July 14, Kexing Biopharm quickly started working on an overseas sales plan for the drug.